Pfizer scraps €400m Dublin facility expansion
November 28, 2016Manufacturing and Production, Sales and Marketing Pfizer, bococizumab
Pfizer has U-turned on its intention to bolster operations at its Grange Castle, Dublin facility in a 34,500 square-metre expansion …
Takeda gains marketing authorisation for multiple myeloma pill
November 28, 2016Sales and Marketing Takeda, multiple myeloma
Takeda Pharmaceutical has announced that they have received conditional marketing authorisation for Ninlaro (ixazomib) for treatment of adult patients with …
GSK applies for EU approval for shingles vaccine
November 28, 2016Sales and Marketing European Commission, GSK, GlaxoSmithKline, Shingrix, shingles
After filing for FDA approval in October, GlaxoSmithKline has now applied for approval from the European Commission (EC) for its …
Taro announces appointment of new CEO
November 25, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Taro pharmaceutical, sun pharmaceutical
Taro Pharmaceutical announced that Uday Baldota will take up the position of CEO and will begin the role in early …
J&J reportedly poised to acquire Europe’s biggest biotech
November 25, 2016Sales and Marketing Actelion, J&J, JJ, Johnson and Johnson, acquisition
Johnson & Johnson could be eyeing a takeover of Swiss biotech Actelion, Europe’s biggest biotech, according to insiders, Bloomberg has …
GSK reaches endgame of race to develop anaemia drug
November 25, 2016Research and Development, Sales and Marketing AstraZeneca, Daprodustat, GSK, GlaxoSmithKline, anaemia
GlaxoSmithKline has announced that they will begin Phase 3 development of their anaemia drug, daprodustat. The drug is an oral …
Top Ten most popular articles on Pharmafile this week
November 25, 2016Medical Communications November, news, pharmaceutical, top 10, top ten, top ten stories
This week has seen the pharmaceutical industry return to business as usual after the presidential election provided a boost to …
Insider interview: Roche discusses efficacy of CDF and NICE
November 25, 2016Medical Communications, Sales and Marketing CDF, NICE, Roche
Deborah Lancaster, Head of Market Access at Roche, discusses, in the latest issue of Pharmafile, the efficacy of the National …
Lowered price wins NICE approval for Janssen leukaemia treatment
November 25, 2016Medical Communications, Sales and Marketing Janssen, NICE, SMC, chronic lymphocytic leukaemia, ibrutinib, imbruvica
After being knocked back in the beginning of June this year, NICE has announced that Janssen’s Imbruvica (ibrutinib) will now …
Opdivo first PD-1 inhibitor given European approval for haematological cancer
November 25, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb
Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …
NICE u-turns on Celgene’s drug for multiple myeloma
November 24, 2016Medical Communications Celgene, NICE, imnovid
NICE has performed a U-turn on Celgene’s Imnovid (pomalidomide) based on new data and the offer of a price reduction. …
Woodley Equipment Exhibiting at Clinical Operations in Oncology Trials Europe
November 24, 2016clinical research, clinicaltrials, oncology
Woodley Equipment is exhibiting at Clinical Operations in Oncology Trials Europe, which is taking place on 29th and 30th November Steigenberger …
Non-small cell lung cancer market to hit $26bn by 2025
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing GlobalData, non-small cell lung cancer
New research from GlobalData has indicated that the non-small cell lung cancer (NSCLC) market will rise in value by over …
Navidea agrees deal worth $310 million with Cardinal
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cardinal, Navidea, Navidea biopharmaceutical
Navidea Biopharmaceuticals, a developer of immunodiagnostic agents and immunotherapeutics, has announced that they will enter into a definitive asset purchase …
Patient deaths lead Juno Therapeutics to halt trial for second time
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing acute lymphoblastic leukaemia, clinical trial deaths, juno therapeutics
Juno Therapeutics has been forced to halt a trial investigating the efficacy of its lead experimental CAR-T cancer treatment JCAR015 …
Lilly forced to abandon Alzheimer’s drug after failed trial
November 24, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alzheimer's, Alzheimer's disease, Eli Lilly
Eli Lilly announced that the results of its ‘Expedition 3’ trial for an experimental Alzheimer’s disease drug meant that they would …
Allergan acquires Chase Pharma in potential $1 billion deal
November 23, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Allergan announced that it has completed the acquisition of Chase Pharmaceutical Corporation in a deal worth a potential $1 billion. …
Anthony Maddaluna, executive vice president of Pfizer, to retire
November 23, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Anthony J. Maddaluna, who worked at Pfizer for more than 41 years, will retire from his positions of executive vice …
Sun Pharma makes strategic Russian firm acquisition
November 23, 2016Research and Development, Sales and Marketing Biosintez, Russia, Sun Pharma
Sun Pharmaceutical, India’s largest pharmaceutical company, has acquired Russian pharmaceutical company JSC Biosintez in a total deal of $60 million. …
Pfizer set to develop new $200 million site
November 23, 2016Manufacturing and Production, Research and Development Pfizer, manufacturing and production
Pfizer plans to expand its operations in St. Louis, Missouri, by developing a $200 million facility in Chesterfield. The site …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
